249 related articles for article (PubMed ID: 35316675)
1. Efficacy of the combination of baricitinib, remdesivir, and dexamethasone in hypoxic adults with COVID-19: A retrospective study.
Yasuda Y; Hirayama Y; Uemasu K; Arasawa S; Iwashima D; Takahashi KI
Respir Med Res; 2022 May; 81():100903. PubMed ID: 35316675
[TBL] [Abstract][Full Text] [Related]
2. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.
Kalil AC; Patterson TF; Mehta AK; Tomashek KM; Wolfe CR; Ghazaryan V; Marconi VC; Ruiz-Palacios GM; Hsieh L; Kline S; Tapson V; Iovine NM; Jain MK; Sweeney DA; El Sahly HM; Branche AR; Regalado Pineda J; Lye DC; Sandkovsky U; Luetkemeyer AF; Cohen SH; Finberg RW; Jackson PEH; Taiwo B; Paules CI; Arguinchona H; Erdmann N; Ahuja N; Frank M; Oh MD; Kim ES; Tan SY; Mularski RA; Nielsen H; Ponce PO; Taylor BS; Larson L; Rouphael NG; Saklawi Y; Cantos VD; Ko ER; Engemann JJ; Amin AN; Watanabe M; Billings J; Elie MC; Davey RT; Burgess TH; Ferreira J; Green M; Makowski M; Cardoso A; de Bono S; Bonnett T; Proschan M; Deye GA; Dempsey W; Nayak SU; Dodd LE; Beigel JH;
N Engl J Med; 2021 Mar; 384(9):795-807. PubMed ID: 33306283
[TBL] [Abstract][Full Text] [Related]
3. Mortality comparision in patients receiving either Remdesivir or Remdesivir plus Baricitinib combination in case of moderate to severe COVID-19 Pneumonia: A retrospective study.
Das D; Mukhopadhyay P; Banerjee D
J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443520
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.
Marconi VC; Ramanan AV; de Bono S; Kartman CE; Krishnan V; Liao R; Piruzeli MLB; Goldman JD; Alatorre-Alexander J; de Cassia Pellegrini R; Estrada V; Som M; Cardoso A; Chakladar S; Crowe B; Reis P; Zhang X; Adams DH; Ely EW;
Lancet Respir Med; 2021 Dec; 9(12):1407-1418. PubMed ID: 34480861
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy with remdesivir and immunomodulators improves respiratory status in COVID-19: A retrospective study.
Kojima Y; Nakakubo S; Kamada K; Yamashita Y; Takei N; Nakamura J; Matsumoto M; Horii H; Sato K; Shima H; Suzuki M; Konno S
J Med Virol; 2022 Dec; 94(12):5702-5712. PubMed ID: 35916111
[TBL] [Abstract][Full Text] [Related]
6. Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial.
Wolfe CR; Tomashek KM; Patterson TF; Gomez CA; Marconi VC; Jain MK; Yang OO; Paules CI; Palacios GMR; Grossberg R; Harkins MS; Mularski RA; Erdmann N; Sandkovsky U; Almasri E; Pineda JR; Dretler AW; de Castilla DL; Branche AR; Park PK; Mehta AK; Short WR; McLellan SLF; Kline S; Iovine NM; El Sahly HM; Doernberg SB; Oh MD; Huprikar N; Hohmann E; Kelley CF; Holodniy M; Kim ES; Sweeney DA; Finberg RW; Grimes KA; Maves RC; Ko ER; Engemann JJ; Taylor BS; Ponce PO; Larson L; Melendez DP; Seibert AM; Rouphael NG; Strebe J; Clark JL; Julian KG; de Leon AP; Cardoso A; de Bono S; Atmar RL; Ganesan A; Ferreira JL; Green M; Makowski M; Bonnett T; Beresnev T; Ghazaryan V; Dempsey W; Nayak SU; Dodd LE; Beigel JH; Kalil AC;
Lancet Respir Med; 2022 Sep; 10(9):888-899. PubMed ID: 35617986
[TBL] [Abstract][Full Text] [Related]
7. Clinical impact of combination therapy with baricitinib, remdesivir, and dexamethasone in patients with severe COVID-19.
Izumo T; Kuse N; Awano N; Tone M; Sakamoto K; Takada K; Muto Y; Fujimoto K; Saiki A; Ito Y; Matsumoto H; Inomata M
Respir Investig; 2021 Nov; 59(6):799-803. PubMed ID: 34413006
[TBL] [Abstract][Full Text] [Related]
8. Perspectives of association Baricitinib/Remdesivir for adults with Covid-19 infection.
Vitiello A; Ferrara F
Mol Biol Rep; 2022 Jan; 49(1):827-831. PubMed ID: 34839450
[TBL] [Abstract][Full Text] [Related]
9. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
[TBL] [Abstract][Full Text] [Related]
10. In adults hospitalized with COVID-19, adding baricitinib vs. dexamethasone to remdesivir did not differ for MV-free survival.
Tran A; Rochwerg B
Ann Intern Med; 2022 Oct; 175(10):JC115. PubMed ID: 36191322
[TBL] [Abstract][Full Text] [Related]
11. A Risk Profile Using Simple Hematologic Parameters to Assess Benefits From Baricitinib in Patients Hospitalized With COVID-19: A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-2.
Paules CI; Wang J; Tomashek KM; Bonnett T; Singh K; Marconi VC; Davey RT; Lye DC; Dodd LE; Yang OO; Benson CA; Deye GA; Doernberg SB; Hynes NA; Grossberg R; Wolfe CR; Nayak SU; Short WR; Voell J; Potter GE; Rapaka RR
Ann Intern Med; 2024 Mar; 177(3):343-352. PubMed ID: 38408357
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of Combination of Baricitinib and Remdesivir in Hospitalized Patients with COVID-19 in the United States: A Modelling Study.
Kelton K; Klein T; Murphy D; Belger M; Hille E; McCollam PL; Spiro T; Burge R
Adv Ther; 2022 Jan; 39(1):562-582. PubMed ID: 34807369
[TBL] [Abstract][Full Text] [Related]
13. Remdesivir in combination with dexamethasone for patients hospitalized with COVID-19: A retrospective multicenter study.
Gressens SB; Esnault V; De Castro N; Sellier P; Sene D; Chantelot L; Hervier B; Delaugerre C; Chevret S; Molina JM;
PLoS One; 2022; 17(2):e0262564. PubMed ID: 35176057
[TBL] [Abstract][Full Text] [Related]
14. Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review.
Cantini F; Goletti D; Petrone L; Najafi Fard S; Niccoli L; Foti R
Drugs; 2020 Dec; 80(18):1929-1946. PubMed ID: 33068263
[TBL] [Abstract][Full Text] [Related]
15. Association and pharmacological synergism of the triple drug therapy baricitinib/remdesivir/rhACE2 for the management of COVID-19 infection.
Vitiello A; Ferrara F
Naunyn Schmiedebergs Arch Pharmacol; 2022 Jan; 395(1):99-104. PubMed ID: 34669002
[TBL] [Abstract][Full Text] [Related]
16. An EUA for baricitinib (Olumiant) for COVID-19.
Med Lett Drugs Ther; 2020 Dec; 62(1614):202-203. PubMed ID: 33451175
[No Abstract] [Full Text] [Related]
17. Remdesivir for the Treatment of Severe COVID-19: A Community Hospital's Experience.
Lee S; Santarelli A; Caine K; Schritter S; Dietrich T; Ashurst J
J Am Osteopath Assoc; 2020 Dec; 120(12):926-933. PubMed ID: 33136164
[TBL] [Abstract][Full Text] [Related]
18. Remdesivir and Its Combination With Repurposed Drugs as COVID-19 Therapeutics.
Chatterjee B; Thakur SS
Front Immunol; 2022; 13():830990. PubMed ID: 35634324
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19.
Garibaldi BT; Wang K; Robinson ML; Zeger SL; Bandeen-Roche K; Wang MC; Alexander GC; Gupta A; Bollinger R; Xu Y
JAMA Netw Open; 2021 Mar; 4(3):e213071. PubMed ID: 33760094
[TBL] [Abstract][Full Text] [Related]
20. Association of Remdesivir Treatment With Survival and Length of Hospital Stay Among US Veterans Hospitalized With COVID-19.
Ohl ME; Miller DR; Lund BC; Kobayashi T; Richardson Miell K; Beck BF; Alexander B; Crothers K; Vaughan Sarrazin MS
JAMA Netw Open; 2021 Jul; 4(7):e2114741. PubMed ID: 34264329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
